Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1861 to 1875 of 7707 results

  1. Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

    In development [GID-TA10596] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Waldenstrom's macroglobulinaemia - ibrutinib [ID884]

    In development [GID-TA10046] Expected publication date: 22 November 2017

    Technology appraisal guidance
    In development

  3. Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]

    In development [GID-TA10966] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154

    Awaiting development [GID-TA10198] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Abatacept for treating active idiopathic inflammatory myopathies TS ID 10095

    Awaiting development [GID-TA10993] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

    In development [GID-TA10089] Expected publication date: 15 November 2017

    Technology appraisal guidance
    In development

  7. Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]

    Awaiting development [GID-TA10605] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]

    In development [GID-TA11036] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Oral semaglutide for managing overweight and obesity [ID6188]

    Awaiting development [GID-TA11149] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]

    Awaiting development [GID-TA10972] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Leriglitazone for treating X-linked andrenoleukodystrophy TS ID 9996

    Awaiting development [GID-TA11393] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868

    Awaiting development [GID-TA11361] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]

    Awaiting development [GID-TA11300] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Edaravone for treating amyotrophic lateral sclerosis TS ID 11869

    Awaiting development [GID-TA11362] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Epilepsies in children, young people and adults (extraordinary review)

    In development [GID-NG10378] Expected publication date: TBC

    NICE guideline
    In development